Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBT (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBT for 16 consecutive years, with -$176000.0 as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 104.27% to -$176000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.2 million, a 411.93% decrease, with the full-year FY2025 number at -$10.2 million, down 879.83% from a year prior.
  • EBT was -$176000.0 for Q4 2025 at Anika Therapeutics, up from -$2.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $24.5 million in Q4 2023 to a low of -$12.0 million in Q1 2023.
  • A 5-year average of -$89000.0 and a median of -$2.1 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 238.38% in 2022, then crashed 788.0% in 2025.
  • Anika Therapeutics' EBT stood at -$9.2 million in 2021, then surged by 238.38% to $12.7 million in 2022, then skyrocketed by 93.43% to $24.5 million in 2023, then crashed by 83.23% to $4.1 million in 2024, then plummeted by 104.27% to -$176000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EBT are -$176000.0 (Q4 2025), -$2.2 million (Q3 2025), and -$4.0 million (Q2 2025).